| 2023/03/21 16:48:47 | |
|---|---|
| Price | |
| 200.00 USD | |
| Difference | 12.84% (22.76) |
General attributes
| ISIN | US81181C1045 |
| Symbol | SGEN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 34,258 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 200.00 USD |
| High | 200.00 USD |
| Low | 200.00 USD |
| Close (prev. day) | 177.2421 USD |
| VWAP | 200.00 USD |
| Volume (pcs) | 34 |
| Trading volume | 6,800.00 |
| Number of trades | 1 |
| Last size | 34 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: SEAGEN INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/06/06 |
|
Global Equity Ratings |
|
| 2023/06/01 |
|
Global Equity Ratings |
|
| 2023/05/24 |
|
Global Equity Ratings |
|
| 2023/05/03 |
|
Global Equity Ratings |
|
| 2023/04/25 |
|
Global Equity Ratings |
|
| 2023/03/21 16:48:47 | |
|---|---|
| Price | |
| 200.00 USD | |
| Difference | 12.84% (22.76) |
General attributes
| ISIN | US81181C1045 |
| Symbol | SGEN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 34,258 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 200.00 USD |
| High | 200.00 USD |
| Low | 200.00 USD |
| Close (prev. day) | 177.2421 USD |
| VWAP | 200.00 USD |
| Volume (pcs) | 34 |
| Trading volume | 6,800.00 |
| Number of trades | 1 |
| Last size | 34 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 0.38 | 0.39 | 0.67 |
| Volatility | - | - | - |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | - USD (24) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 12.57 USD (71) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 7.47 USD (58) |
| Ø price 250 days | Ø volume 250 days (pcs.) | - USD (57) |
| YTD High | date | 200.00 USD (2023/03/21) |
| YTD Low | date | 177.24 USD (2023/03/02) |
| 52 Weeks High | date | 200.00 USD (2023/03/21) |
| 52 Weeks Low | date | 177.24 USD (2023/03/02) |
All listings for SEAGEN INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Tradegate | 2023/06/07 | 09:32 | 183.70 EUR | 0.00 | 1 |
| Stuttgart | 2023/06/07 | 08:06 | 182.30 EUR | 0.00 | 1 |
| Nasdaq | 2023/06/06 | 22:00 | 195.47 USD | 118.39 | 10,246 |
| Munich | 2023/06/07 | 08:00 | 181.90 EUR | 0.00 | 1 |
| London Stock Exchange | 2023/03/21 | 16:48 | 200.00 USD | 0.01 | 1 |
| Frankfurt | 2023/06/07 | 09:19 | 182.00 EUR | 0.00 | 1 |
| Berlin | 2023/06/07 | 08:08 | 182.10 EUR | 0.00 | 1 |
| BX Swiss | - | - | - | 0.00 | - |
Company Logo
Contact Details
| SEAGEN INC. |
| - - |
| 21823 30th Drive South East - 98021 Bothell |
| Telefon: +1-425-527-4000 |
| Fax: + |
| E-mail: contact@seagen.com |
PDF Downloads
| Company report: SEAGEN INC. | |
Company Profile
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. |
Members of Management Board
| Felix Baker | Chairman of Board of Directors |
| Alpna Seth | Member of Board of Directors |
| Nancy Simonian | Member of Board of Directors |
| Sandra Swain | Member of Board of Directors |
| Ted Love | Member of Board of Directors |
| Daniel Welch | Member of Board of Directors |
| David Gryska | Member of Board of Directors |
| John Orwin | Member of Board of Directors |
| Clay B. Siegall | Chairman of Managing Board |
| Vaughn B. Himes | Member of Executive Committee |
| Charles Romp | Member of Executive Committee |
| Christopher Pawlowicz | Member of Executive Committee |
| Jean I. Liu | Member of Executive Committee |
| Natasha Hernday | Member of Executive Committee |
| Roger D. Dansey, M.D. | Member of Executive Committee |
| Todd E. Simpson | Member of Executive Committee |
| Tuomo Pätsi | Member of Executive Committee |